NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News $134.59 +0.34 (+0.25%) (As of 02/9/2024 08:56 PM ET) Add Compare Share Share Today's Range$133.92▼$134.8950-Day Range$122.90▼$139.3952-Week Range$111.83▼$139.49Volume1.68 million shsAverage Volume1.86 million shsMarket Capitalization$7.47 billionAssets Under Management$7.44 billionDividend Yield0.26%Net Expense Ratio0.44% Stock AnalysisStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestSocial MediaStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestSocial Media Get iShares Biotechnology ETF alerts: Email Address About iShares Biotechnology ETF (NASDAQ:IBB)iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Read More IBB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBB ETF News HeadlinesFebruary 6, 2024 | americanbankingnews.comiShares Biotechnology ETF Sees Unusually Large Options Volume (NASDAQ:IBB)January 29, 2024 | benzinga.comAI, Biotech, Energy Sectors Expect M&A Revival For 2024February 12, 2024 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.January 24, 2024 | finance.yahoo.comDaily Spotlight: Biotech Sector Catches FireJanuary 4, 2024 | msn.comBiogen, Neurocrine, and more are Bairds top picks for biotech in 2024December 31, 2023 | finance.yahoo.comIBB Dec 2023 129.000 putDecember 29, 2023 | msn.comTop Biotech Picks For 2024: Piper Sandler Foresees Potential Sector ComebackDecember 26, 2023 | msn.comBiotech Stocks Are Breaking Out—and They Show No Sign of Slowing DownFebruary 12, 2024 | Stansberry Research (Ad)Tech insider: "Watch your mailbox"You could soon get a strange package from the Federal Government. It's part of the biggest overhaul to our money in decades. And it could change your life (and retirement) in ways that'll surprise you.December 20, 2023 | markets.businessinsider.comWall Street Edges Higher, Small Caps Eye Best Month In 3 Years, Bitcoin Rebounds: What's Driving Markets Wednesday?See More Headlines Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkICE Biotechnology Index (TR) (USD) CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings231 Fund Statistics Assets Under Management$7.44 billion Average Daily Volume$1.79 million Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorJPMorgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume4,365 Put Options3,900 Call Options465 Short Interest8,740,000 shs Miscellaneous Outstanding Shares55,500,000Beta0.73 Creation Unit50,000 Creation Fee$614.00 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.44%0.57%0.54%0.47%0.51%Other Expenses0.00%0.40%0.54%0.33%0.58%Total Expense0.44%0.72%0.70%0.57%0.70%Fee Waiver0.00%-0.53%-0.55%-0.20%-0.57%Net Expense0.44%0.61%0.60%0.53%0.58% iShares Biotechnology ETF (IBB) Holdings & ExposureTop 10 IBB HoldingsAmgen(NASDAQ:AMGN)Holding Weight: 8.83%Vertex Pharmaceuticals(NASDAQ:VRTX)Holding Weight: 8.33%Gilead Sciences(NASDAQ:GILD)Holding Weight: 8.19%Regeneron Pharmaceuticals(NASDAQ:REGN)Holding Weight: 7.67%IQVIA(NYSE:IQV)Holding Weight: 3.80%Biogen(NASDAQ:BIIB)Holding Weight: 3.68%Seagen(NASDAQ:SGEN)Holding Weight: 3.41%Moderna(NASDAQ:MRNA)Holding Weight: 3.39%Illumina(NASDAQ:ILMN)Holding Weight: 2.82%Mettler-Toledo International(NYSE:MTD)Holding Weight: 2.63%IBB Sector ExposureIBB Industry ExposureFull Holdings Details Key ExecutivesGeorge G. C. Parker Ph.D.Independent Chairman of the Board of TrusteesMichael Arthur LathamPresident, TrusteeJack GeeChief Financial Officer, TreasurerGeoffrey D. FlynnChief Operating Officer, Executive Vice PresidentBio & Compensation - Amy SchioldagerExecutive Vice PresidentIra P. ShapiroVice President, Chief Legal OfficerMatt TuckerVice PresidentBio & Compensation - Eilleen M. ClavereSecretaryCecilia H. HerbertIndependent TrusteeCharles A. HurtyIndependent TrusteeMore ExecutivesSimilar ETFsVanEck Pharmaceutical ETFNASDAQ:PPHVanEck Biotech ETFNASDAQ:BBHInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHInvesco Dorsey Wright Healthcare Momentum ETFNASDAQ:PTHProShares Ultra Nasdaq BiotechnologyNASDAQ:BIBInstitutional OwnershipGladstone Institutional Advisory LLCBought 420 shares on 2/9/2024Ownership: 0.011%Abbot Financial Management Inc.Sold 184 shares on 2/9/2024Ownership: 0.007%Congress Wealth Management LLC DE Sold 382 shares on 2/9/2024Ownership: 0.003%Avantax Planning Partners Inc.Sold 85 shares on 2/9/2024Ownership: 0.003%Crewe Advisors LLCBought 78 shares on 2/9/2024Ownership: 0.000%View All Institutional Transactions IBB ETF - Frequently Asked Questions How have IBB shares performed in 2024? iShares Biotechnology ETF's stock was trading at $135.85 at the start of the year. Since then, IBB stock has decreased by 0.9% and is now trading at $134.59. View the best growth stocks for 2024 here. How often does iShares Biotechnology ETF pay dividends? What is the dividend yield for iShares Biotechnology ETF? iShares Biotechnology ETF announced a quarterly dividend on Tuesday, December 19th. Stockholders of record on Thursday, December 21st will be given a dividend of $0.124 per share on Wednesday, December 27th. This represents a $0.50 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date is Wednesday, December 20th. Read our dividend analysis for IBB. What does IBB invest in? iShares Biotechnology ETF is a equity fund issued by iShares. IBB focuses on health care investments and follows the ICE Biotechnology Index (TR) (USD). The fund's investments total to approximately $7.44 billion assets under management. What stocks does iShares Biotechnology ETF hold? IBB invests in 231 holdings. Some of the stocks in their portfolio include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), IQVIA (IQV), Biogen (BIIB), Seagen (SGEN), Moderna (MRNA), Illumina (ILMN) and Mettler-Toledo International (MTD). What is the management fee for iShares Biotechnology ETF? iShares Biotechnology ETF's management fee is 0.44% and has no other recorded expenses or fee waivers. The net expense ratio for IBB is 0.44%. When did iShares Biotechnology ETF's stock split? iShares Biotechnology ETF's stock split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were payable to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Biotechnology ETF investors own include NVIDIA (NVDA), Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL). Who are iShares Biotechnology ETF's major shareholders? iShares Biotechnology ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include Commerce Bank (1.31%), Wells Fargo & Company MN (1.20%), International Assets Investment Management LLC (1.01%), PNC Financial Services Group Inc. (0.70%), Bank Julius Baer & Co. Ltd Zurich (0.53%) and Bronte Capital Management Pty Ltd. (0.51%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IBB) was last updated on 2/12/2024 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.